ARTH
Price
$0.25
Change
+$0.06 (+31.58%)
Updated
Jan 17 closing price
Capitalization
1.11M
BETRF
Price
$0.07
Change
-$0.01 (-12.50%)
Updated
Jan 17 closing price
Capitalization
10.35M
Ad is loading...

ARTH vs BETRF

Header iconARTH vs BETRF Comparison
Open Charts ARTH vs BETRFBanner chart's image
Arch Therapeutics
Price$0.25
Change+$0.06 (+31.58%)
Volume$5.91K
Capitalization1.11M
BETTERLIFE PHARMA
Price$0.07
Change-$0.01 (-12.50%)
Volume$21.88K
Capitalization10.35M
ARTH vs BETRF Comparison Chart
Loading...
ARTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BETRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARTH vs. BETRF commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARTH is a Hold and BETRF is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (ARTH: $0.25 vs. BETRF: $0.07)
Brand notoriety: ARTH and BETRF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARTH: 73% vs. BETRF: 107%
Market capitalization -- ARTH: $1.11M vs. BETRF: $10.35M
ARTH [@Biotechnology] is valued at $1.11M. BETRF’s [@Biotechnology] market capitalization is $10.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARTH’s FA Score shows that 0 FA rating(s) are green whileBETRF’s FA Score has 0 green FA rating(s).

  • ARTH’s FA Score: 0 green, 5 red.
  • BETRF’s FA Score: 0 green, 5 red.
According to our system of comparison, BETRF is a better buy in the long-term than ARTH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARTH’s TA Score shows that 1 TA indicator(s) are bullish while BETRF’s TA Score has 4 bullish TA indicator(s).

  • ARTH’s TA Score: 1 bullish, 5 bearish.
  • BETRF’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, BETRF is a better buy in the short-term than ARTH.

Price Growth

ARTH (@Biotechnology) experienced а +46.97% price change this week, while BETRF (@Biotechnology) price change was -16.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

ARTH is expected to report earnings on Aug 30, 2023.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BETRF($10.4M) has a higher market cap than ARTH($1.11M). ARTH YTD gains are higher at: 47.059 vs. BETRF (-6.977). BETRF has higher annual earnings (EBITDA): -3.14M vs. ARTH (-8.68M). ARTH has more cash in the bank: 30K vs. BETRF (18.7K). BETRF has less debt than ARTH: BETRF (1.24M) vs ARTH (9.39M). ARTH has higher revenues than BETRF: ARTH (148K) vs BETRF (0).
ARTHBETRFARTH / BETRF
Capitalization1.11M10.4M11%
EBITDA-8.68M-3.14M276%
Gain YTD47.059-6.977-675%
P/E RatioN/AN/A-
Revenue148K0-
Total Cash30K18.7K160%
Total Debt9.39M1.24M758%
FUNDAMENTALS RATINGS
ARTH vs BETRF: Fundamental Ratings
ARTH
BETRF
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6562
P/E GROWTH RATING
1..100
10047
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARTH's Valuation (87) in the null industry is in the same range as BETRF (100). This means that ARTH’s stock grew similarly to BETRF’s over the last 12 months.

ARTH's Profit vs Risk Rating (100) in the null industry is in the same range as BETRF (100). This means that ARTH’s stock grew similarly to BETRF’s over the last 12 months.

ARTH's SMR Rating (100) in the null industry is in the same range as BETRF (100). This means that ARTH’s stock grew similarly to BETRF’s over the last 12 months.

BETRF's Price Growth Rating (62) in the null industry is in the same range as ARTH (65). This means that BETRF’s stock grew similarly to ARTH’s over the last 12 months.

BETRF's P/E Growth Rating (47) in the null industry is somewhat better than the same rating for ARTH (100). This means that BETRF’s stock grew somewhat faster than ARTH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARTHBETRF
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 12 days ago
90%
Bearish Trend 12 days ago
90%
Momentum
ODDS (%)
Bearish Trend 12 days ago
90%
Bullish Trend 12 days ago
78%
MACD
ODDS (%)
Bearish Trend 12 days ago
90%
Bullish Trend 12 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 12 days ago
77%
Bullish Trend 12 days ago
74%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
75%
Bullish Trend 12 days ago
79%
Advances
ODDS (%)
N/A
Bullish Trend 28 days ago
75%
Declines
ODDS (%)
Bearish Trend 21 days ago
90%
N/A
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
89%
Bearish Trend 12 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 12 days ago
90%
View a ticker or compare two or three
Ad is loading...
ARTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BETRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OCLGX13.590.15
+1.12%
Optimum Large Cap Growth C
DESUX23.320.23
+1.00%
DWS ESG Core Equity R6
WEECX11.290.06
+0.53%
TETON Westwood Equity A
OSGIX41.090.19
+0.46%
JPMorgan Mid Cap Growth A
EPSRX22.120.08
+0.36%
NYLI Epoch Global Equity Yield Class R6

ARTH and

Correlation & Price change

A.I.dvisor tells us that ARTH and EDSA have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ARTH and EDSA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARTH
1D Price
Change %
ARTH100%
+28.21%
EDSA - ARTH
21%
Poorly correlated
+0.60%
HRMY - ARTH
20%
Poorly correlated
+1.32%
BIVI - ARTH
13%
Poorly correlated
+0.45%
APLIF - ARTH
12%
Poorly correlated
N/A
BETRF - ARTH
5%
Poorly correlated
-10.67%
More

BETRF and

Correlation & Price change

A.I.dvisor tells us that BETRF and ATXI have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BETRF and ATXI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BETRF
1D Price
Change %
BETRF100%
-10.67%
ATXI - BETRF
21%
Poorly correlated
+5.71%
CLABF - BETRF
20%
Poorly correlated
-52.71%
AVCTF - BETRF
15%
Poorly correlated
N/A
ARTH - BETRF
5%
Poorly correlated
+28.21%
BSEM - BETRF
3%
Poorly correlated
+1.15%
More